Weight loss drug and IUD for early uterine cancer
Treatments studied
Part of Women’s health & pregnancy clinical trials.
This study tests a weight-loss drug (tirzepatide) combined with a hormone-releasing IUD to treat certain early-stage uterine conditions without surgery. It may help women who are overweight or obese and want to avoid hysterectomy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have atypical hyperplasia or grade 1 endometrial cancer and want a non-surgical treatment.
- You are overweight (BMI 27+) with a related health problem like high blood pressure, diabetes, or high cholesterol, OR you are obese (BMI 30+).
- You have not used any GLP-1 medications (such as liraglutide or semaglutide) or insulin before.
- You do not have a personal or family history of a certain type of thyroid cancer or a condition called MEN2.
- You are willing to have a progestin intrauterine device (IUD) placed and receive weekly injections of tirzepatide.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a weight-loss medication (tirzepatide) can help shrink early-stage, low-grade endometrial cancer or atypical hyperplasia while you keep your uterus for future pregnancy. It is designed for women who are overweight and wish to preserve their fertility.
This study tests whether a diabetes medication called tirzepatide, combined with a hormone-releasing device, can help shrink or stop early-stage endometrial cancer (cancer of the uterine lining) in patients who are overweight and either cannot have surgery right away or prefer to delay it. The goal is to see if this approach can be an alternative to immediate surgery.
This trial tests if tirzepatide, a drug that helps with weight loss, can improve outcomes for women with obesity and certain early-stage endometrial conditions before a planned hysterectomy.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
This trial tests if adding a GLP-1 weight-loss drug to a hormone-releasing IUD can help treat very early endometrial cancer or a precancerous condition in women with obesity. The goal is to see if this combination is effective without surgery.
This study tests if adding a weight loss medication (tirzepatide or semaglutide) during chemotherapy helps people with early-stage endometrial cancer who are overweight or have diabetes. It aims to see if weight loss can improve treatment outcomes.
Hear when a new Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.